Summary
Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H2 2016’, provides an overview of the Allergic Asthma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
- The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Asthma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Amgen Inc.
Aquinox Pharmaceuticals Inc.
ASIT biotech s.a.
Aslan Pharmaceuticals Pte. Ltd.
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Limited
F. Hoffmann-La Roche Ltd.
Fountain Biopharma Inc.
Genentech, Inc.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
Infinity Pharmaceuticals, Inc.
KPI Therapeutics, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
Mycenax Biotech Inc.
NeoPharm Co., Ltd.
Oxagen Limited
Panacea Biotec Limited
Paradigm Biopharmaceuticals Limited
Pharmaxis Limited
Protectimmun GmbH
Shire Plc
Stallergenes Greer plc
sterna biologicals Gmbh & Co KG
Swecure AB
Synermore Biologics Co Ltd
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
Xencor, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Asthma Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Asthma - Overview 9
Pipeline Products for Allergic Asthma - Comparative Analysis 10
Allergic Asthma - Therapeutics under Development by Companies 11
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 14
Allergic Asthma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Allergic Asthma - Products under Development by Companies 18
Allergic Asthma - Products under Investigation by Universities/Institutes 21
Allergic Asthma - Companies Involved in Therapeutics Development 22
ALK-Abello A/S 22
Allergopharma GmbH & Co. KG 23
Amgen Inc. 24
Aquinox Pharmaceuticals Inc. 25
ASIT biotech s.a. 26
Aslan Pharmaceuticals Pte. Ltd. 27
Chiesi Farmaceutici SpA 28
Circassia Pharmaceuticals Plc 29
CSL Limited 30
F. Hoffmann-La Roche Ltd. 31
Fountain Biopharma Inc. 32
Genentech, Inc. 33
GlaxoSmithKline Plc 34
Hydra Biosciences, Inc. 35
Infinity Pharmaceuticals, Inc. 36
KPI Therapeutics, Inc. 37
Mabtech Limited 38
Marinomed Biotechnologie GmbH 39
Mycenax Biotech Inc. 40
NeoPharm Co., Ltd. 41
Oxagen Limited 42
Panacea Biotec Limited 43
Paradigm Biopharmaceuticals Limited 44
Pharmaxis Limited 45
Protectimmun GmbH 46
Shire Plc 47
Stallergenes Greer plc 48
sterna biologicals Gmbh & Co KG 49
Swecure AB 50
Synermore Biologics Co Ltd 51
The International Biotechnology Center (IBC) Generium 52
Verona Pharma Plc 53
Xencor, Inc. 54
Allergic Asthma - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
AcTMP-1 - Drug Profile 67
Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile 68
AQX-1125 - Drug Profile 69
Arabinogalactan - Drug Profile 74
ASLAN-004 - Drug Profile 75
ASM-8 - Drug Profile 76
beta-escin - Drug Profile 78
CHF-6001 - Drug Profile 79
CSL-311 - Drug Profile 81
dalazatide - Drug Profile 82
Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 87
duvelisib - Drug Profile 88
EP-67 - Drug Profile 99
Epsi-Gam - Drug Profile 100
FB-825 - Drug Profile 102
GNR-044 - Drug Profile 103
GSK-2245035 - Drug Profile 104
hdm-ASIT - Drug Profile 106
HX-100 - Drug Profile 107
Lactococcus lactis G121 - Drug Profile 109
Leukothera - Drug Profile 110
OC-000459 - Drug Profile 111
OC-2417 - Drug Profile 113
omalizumab biosimilar - Drug Profile 114
omalizumab biosimilar - Drug Profile 115
omalizumab biosimilar - Drug Profile 116
omalizumab biosimilar - Drug Profile 117
omalizumab biosimilar - Drug Profile 118
OND-86 - Drug Profile 119
pemirolast potassium - Drug Profile 120
pentosan polysulfate sodium - Drug Profile 121
RG-6149 - Drug Profile 122
RG-7990 - Drug Profile 123
RPL-554 - Drug Profile 124
SB-010 - Drug Profile 132
SG-100 - Drug Profile 134
SM-301 - Drug Profile 136
Small Molecule for Allergic Asthma - Drug Profile 137
Small Molecules for Allergic Asthma - Drug Profile 138
Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma - Drug Profile 139
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 140
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 141
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 144
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 146
SWE-01 - Drug Profile 151
Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis - Drug Profile 152
tezepelumab - Drug Profile 153
Vaccine for Allergic Asthma - Drug Profile 155
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 156
XmAb-7195 - Drug Profile 158
Allergic Asthma - Dormant Projects 159
Allergic Asthma - Discontinued Products 163
Allergic Asthma - Product Development Milestones 164
Featured News & Press Releases 164
Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 176
Contact Us 176
Disclaimer 177
List of Tables
Number of Products under Development for Allergic Asthma, H2 2016 13
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2016 25
Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2016 26
Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H2 2016 27
Allergic Asthma - Pipeline by Amgen Inc., H2 2016 28
Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016 29
Allergic Asthma - Pipeline by ASIT biotech s.a., H2 2016 30
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016 31
Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H2 2016 32
Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 33
Allergic Asthma - Pipeline by CSL Limited, H2 2016 34
Allergic Asthma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 35
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2016 36
Allergic Asthma - Pipeline by Genentech, Inc., H2 2016 37
Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H2 2016 38
Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H2 2016 39
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 40
Allergic Asthma - Pipeline by KPI Therapeutics, Inc., H2 2016 41
Allergic Asthma - Pipeline by Mabtech Limited, H2 2016 42
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2016 43
Allergic Asthma - Pipeline by Mycenax Biotech Inc., H2 2016 44
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2016 45
Allergic Asthma - Pipeline by Oxagen Limited, H2 2016 46
Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2016 47
Allergic Asthma - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 48
Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2016 49
Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2016 50
Allergic Asthma - Pipeline by Shire Plc, H2 2016 51
Allergic Asthma - Pipeline by Stallergenes Greer plc, H2 2016 52
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 53
Allergic Asthma - Pipeline by Swecure AB, H2 2016 54
Allergic Asthma - Pipeline by Synermore Biologics Co Ltd, H2 2016 55
Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 56
Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2016 57
Allergic Asthma - Pipeline by Xencor, Inc., H2 2016 58
Assessment by Monotherapy Products, H2 2016 59
Assessment by Combination Products, H2 2016 60
Number of Products by Stage and Target, H2 2016 62
Number of Products by Stage and Mechanism of Action, H2 2016 65
Number of Products by Stage and Route of Administration, H2 2016 68
Number of Products by Stage and Molecule Type, H2 2016 70
Allergic Asthma - Dormant Projects, H2 2016 163
Allergic Asthma - Dormant Projects (Contd..1), H2 2016 164
Allergic Asthma - Dormant Projects (Contd..2), H2 2016 165
Allergic Asthma - Dormant Projects (Contd..3), H2 2016 166
Allergic Asthma - Discontinued Products, H2 2016 167
List of Figures
Number of Products under Development for Allergic Asthma, H2 2016 13
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 59
Assessment by Combination Products, H2 2016 60
Number of Products by Top 10 Targets, H2 2016 61
Number of Products by Stage and Top 10 Targets, H2 2016 61
Number of Products by Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64
Number of Products by Top 10 Routes of Administration, H2 2016 67
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 67
Number of Products by Top 10 Molecule Types, H2 2016 69
Number of Products by Stage and Top 10 Molecule Types, H2 2016 69
